HIV /AIDS: TREATMENT OF HIV BY ARV MEDICINE IS INDEPENDANT OF CD4 COUNT,VIRAL LOAD GUIDES IT,CLINICAL SYMPTOMS AND VIRAL LOAD WITH DRUG SENSITIVITY GUIDE LINE OF THERAPY
HIV /AIDS: TREATMENT OF HIV BY ARV MEDICINE IS INDEPENDANT OF CD4 COUNT,VIRAL LOAD GUIDES IT,CLINICAL SYMPTOMS AND VIRAL LOAD WITH DRUG SENSITIVITY GUIDE LINE OF THERAPY .
PROF.DRRAM ,HIV/AIDS,SEX DIS.,SEX WEAK.& ABORTION SPECIALIST
profdrram@gmail.com,+917838059592,+919832025033,DELHI –NCR,IND
HIV/ AIDS,CANCER LATEST MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/drramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
The latest revision to the official U.S. HIV treatment guidelines highlights the growing number of excellent first-line HIV treatment regimens and a deepening agreement among experts that viral load, not CD4 count, is what really matters when gauging treatment success.
The revised guidelines, posted to AIDSinfo on May 1, represent the cumulative wisdom of a diverse panel of HIV experts convened by the U.S. Department of Health and Human Services (DHHS). This marks the first full update to the guidelines since Feb. 12, 2013.
Among the most noteworthy changes this time around:
CD4 testing can become less frequent if treatment is going well. In fact, for people who have been on HIV meds for two or more years and have a consistently undetectable viral load, CD4 tests are now only recommended once per year if their count is 300 or higher -- and if it's over 500, CD4 testing is now considered to be completely optional.
Treatemt now not dependant on CD4 count ,no routine regular 03 months its checkup is required if general condiotn of patient is ood and his clinical condition good or viral load remains low we have to continue with same medicines and repeating Viral load test only 06-12 months ,with low viral load patient cam mix with partner during sex without condom for having baby 1-2 times only or relatives in home intimately without fear until blood mixing is present or no such fear of transmission and life is also good as with single tablet drug adherance is good and side effects are also less.
Testing other T cell levels is not generally recommended. Looking at CD8, CD19 and other types of immune cell numbers adds expense to a person's medical care without providing clinical value, the expert panel suggests.
New guidance on HIV treatment switching has been added. The decision of whether to change regimens -- and what to change to -- can often be complicated, especially if they're technically doing well (meaning their viral load is suppressed) on their current regimen. The guidelines have added a bushel of expert advice regarding regimen switches when a person can't or shouldn't remain on their current HIV meds, whether due to severe side effects or other issues like economical or unavailability of drug s.IF GOOD VIRAL LOAD,AFFORDIBILITY AND AVIALABILITY THEN DONOT CHANGE MEDICINE if clinically patient deteriting then do viral load with drug sensitivity if affordable or HIV Genotype studies and decide drug as per sensitivity or if not possible then do it takin combinations of rest of drugs from PROTEASE INHIVITOR AS ATAZANAVIR BOOSTED WITH RITOVAVIR,DARUNAVIR,TIPRANAVIR ,FOSAMPRENAVIR OR ADD FUSION INHIBITOR OR INTEGRASE INHIBITOR . — with AidsControl Empl India and 19 others. (4 photos)
PROF.DRRAM ,HIV/AIDS,SEX DIS.,SEX WEAK.& ABORTION SPECIALIST
profdrram@gmail.com,+917838059592,+919832025033,DELHI –NCR,IND
HIV/ AIDS,CANCER LATEST MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/drramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram
The latest revision to the official U.S. HIV treatment guidelines highlights the growing number of excellent first-line HIV treatment regimens and a deepening agreement among experts that viral load, not CD4 count, is what really matters when gauging treatment success.
The revised guidelines, posted to AIDSinfo on May 1, represent the cumulative wisdom of a diverse panel of HIV experts convened by the U.S. Department of Health and Human Services (DHHS). This marks the first full update to the guidelines since Feb. 12, 2013.
Among the most noteworthy changes this time around:
CD4 testing can become less frequent if treatment is going well. In fact, for people who have been on HIV meds for two or more years and have a consistently undetectable viral load, CD4 tests are now only recommended once per year if their count is 300 or higher -- and if it's over 500, CD4 testing is now considered to be completely optional.
Treatemt now not dependant on CD4 count ,no routine regular 03 months its checkup is required if general condiotn of patient is ood and his clinical condition good or viral load remains low we have to continue with same medicines and repeating Viral load test only 06-12 months ,with low viral load patient cam mix with partner during sex without condom for having baby 1-2 times only or relatives in home intimately without fear until blood mixing is present or no such fear of transmission and life is also good as with single tablet drug adherance is good and side effects are also less.
Testing other T cell levels is not generally recommended. Looking at CD8, CD19 and other types of immune cell numbers adds expense to a person's medical care without providing clinical value, the expert panel suggests.
New guidance on HIV treatment switching has been added. The decision of whether to change regimens -- and what to change to -- can often be complicated, especially if they're technically doing well (meaning their viral load is suppressed) on their current regimen. The guidelines have added a bushel of expert advice regarding regimen switches when a person can't or shouldn't remain on their current HIV meds, whether due to severe side effects or other issues like economical or unavailability of drug s.IF GOOD VIRAL LOAD,AFFORDIBILITY AND AVIALABILITY THEN DONOT CHANGE MEDICINE if clinically patient deteriting then do viral load with drug sensitivity if affordable or HIV Genotype studies and decide drug as per sensitivity or if not possible then do it takin combinations of rest of drugs from PROTEASE INHIVITOR AS ATAZANAVIR BOOSTED WITH RITOVAVIR,DARUNAVIR,TIPRANAVIR ,FOSAMPRENAVIR OR ADD FUSION INHIBITOR OR INTEGRASE INHIBITOR . — with AidsControl Empl India and 19 others. (4 photos)
Comments
Post a Comment